NewAmsterdam Pharma Company N.V. (NAMS)

Market Cap	1.62B
Revenue (ttm)	7.42M
Net Income (ttm)	-229.40M
Shares Out	90.02M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,747
Open	17.87
Previous Close	17.82
Day's Range	17.20 - 18.53
52-Week Range	8.64 - 26.35
Beta	-0.00
Analysts	Strong Buy
Price Target	33.80 (+87.47%)
Earnings Date	n/a

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: NAMS
• Website: https://www.newamsterdampharma.com

Financial Performance

In 2023, NAMS's revenue was $14.09 million, a decrease of -86.28% compared to the previous year's $102.69 million. Losses were -$176.94 million, 681.7% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price forecast is $33.8, which is an increase of 87.47% from the latest price.

Price Target

$33.8

(87.47% upside)

Analyst Consensus: Strong Buy